Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
2.480
+0.010 (0.40%)
At close: Dec 5, 2025, 4:00 PM EST
2.570
+0.090 (3.63%)
After-hours: Dec 5, 2025, 6:51 PM EST

Chemomab Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Net Income
--13.95-24.22-27.65-12.48-5.95
Upgrade
Depreciation & Amortization
-0.050.070.060.030.02
Upgrade
Stock-Based Compensation
-0.621.493.212.020.13
Upgrade
Change in Accounts Receivable
--0.490.9-0.06-2.06-0.1
Upgrade
Change in Accounts Payable
-0.15-1.170.351.180.07
Upgrade
Change in Other Net Operating Assets
--1.77-0.683.72-1.070.59
Upgrade
Operating Cash Flow
--15.39-23.61-20.37-12.37-5.24
Upgrade
Capital Expenditures
---0-0.07-0.24-0.04
Upgrade
Sale of Property, Plant & Equipment
----1-
Upgrade
Investment in Securities
-2.315.8819.6-45.95-0.02
Upgrade
Other Investing Activities
----0-
Upgrade
Investing Cash Flow
-2.315.8819.53-45.19-0.06
Upgrade
Issuance of Common Stock
-9.873.50.4158.651.25
Upgrade
Repurchase of Common Stock
----1.22--
Upgrade
Other Financing Activities
----2.43-
Upgrade
Financing Cash Flow
-9.873.5-0.8161.074.75
Upgrade
Net Cash Flow
--3.22-4.23-1.653.51-0.55
Upgrade
Free Cash Flow
--15.39-23.61-20.44-12.61-5.28
Upgrade
Free Cash Flow Per Share
--3.43-8.04-7.18-4.86-3.09
Upgrade
Cash Income Tax Paid
---0.19-0.35--
Upgrade
Levered Free Cash Flow
--10.86-15.49-10.87-6.07-2.56
Upgrade
Unlevered Free Cash Flow
--10.86-15.49-10.87-6-2.56
Upgrade
Change in Working Capital
--2.11-0.954.01-1.950.56
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.